The combination microarray patch for drug delivery and electrochemotherapy device is a medical device for delivering two separate pharmaceutical preparations to a patient, as well as providing electrostimulation for electroactive pharmaceuticals. A first pharmaceutical preparation is manually delivered into the patient through a first set of drug delivery needles. Similarly, a second pharmaceutical preparation is manually delivered into a patient through a second set of drug delivery needles. A desired electrical potential may then be selectively applied across first and second sets of electrotherapy needles for electroporation to facilitate delivery of the pharmaceutical preparations. The second pharmaceutical preparation may be a conjugate of the first for targeted drug delivery.

A system including a data-driven controller configured to output signals controlling a dose of therapy to a treatment site and in response to feedback comprising data representing a healing state of the treatment site measured by a sensor; and a pumping system coupled to the controller, the pumping system pumping the therapy to the treatment site.

Disclosed are electrostimulative grafts that include at least one galvanic couple with an anode spaced from a cathode. The anode and cathode can be made from biodegradable metals. The graft can include a porous graft matrix material receptive to tissue ingrowth that occurs between the anode and cathode. The electrostimulation provided by the galvanic couple after implantation of the graft can impact the development of tissue within and/or around the porous graft matrix material. Also disclosed are methods for making electrostimulative grafts and for galvanically electrostimulating tissue growth in a porous graft matrix material.

Electrotransport drug delivery devices, system and methods of using configured to determine if a current is present between the anode and cathode when drug is not intended to be delivered by the device. These devices/systems may include an off-current module to determine that any current (e.g., which may be inferred by measuring potential difference between the anode and cathode of the device) flowing between the anode and cathode is below a threshold value when the device is not supposed to be delivering drug, thereby preventing unintended delivery of drug and/or alerting a user that unintended delivery of drug may occur.

A flexible device having a layered structure for delivering electrical stimulation and one or both of light and ultrasound to a skin surface is provided. The device is flexible so as to form a non-planar contact surface against the skin surface, and includes one or both of (a) a flexible light emitter layer positioned between two flexible conductive layers that emits light when driven by a power source and (b) a flexible ultrasound emitter layer positioned between two flexible conductive layers that produces ultrasound when driven by a power source. The device also includes a flexible electrical stimulation layer that functions as an electrode and is configured to provide electrical stimulation when driven by a power source.

A device for delivering light and ultrasound across a skin surface is provided. The device has a layered structure comprising a light source and an ultrasonic transducer. The light source comprises a flexible light emitter layer electrically coupled to a first conductive layer and a second conductive layer, wherein at least one of the first and second conductive layers is transparent. The ultrasonic transducer comprises a flexible ultrasound emitter layer electrically coupled to a third conductive layer and a fourth conductive layer. In one embodiment, the light source comprises an organic light emitting diode or a plurality of printed light emitting diodes and the ultrasonic transducer comprises a piezoelectric coating. The device may be provided with a therapeutic or cosmetic composition to be applied to the skin surface, wherein the light and ultrasound emitted from the device cause transdermal transport of the composition through the skin surface.

The present disclosure also provides for a composition comprising a combination of (a) NAD+, and (b) one or more additional therapeutic compounds, wherein one or more additional therapeutic compounds are compatible with transdermal delivery, such as iontophoretic delivery, while providing minimal skin irritation.